Author

K. L. Swancutt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Assay:imaging· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

T. A. Aguilera· 2 shared A. Facoetti· 1 shared A. J. Davis· 1 shared A. Pompos· 1 shared B. J. Sishc· 1 shared C. E. Martina· 1 shared C. Hamilton· 1 shared E. Elghonaimy· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

T. A. Aguilera

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Defective Homologous Recombination and Genomic Instability Predict Increased Responsiveness to Carbon Ion Radiotherapy in Pancreatic Cancer

B. J. Sishc, J. Saha, E. Polsdofer, L. Ding, H. Lu, S.-Y. Wang, K. L. Swancutt, J. H. Nicholson, A. Facoetti, A. Pompos, M. Ciocca, T. A. Aguilera, M. D. Story, A. J. Davis

This study identifies PDAC cell lines defective in homologous recombination or with high genomic instability as more responsive to carbon ion radiotherapy, suggesting potential for targeted therapy.

bioRxiv · Apr 8, 2024Cancer Biology

Simultaneous selection of nanobodies for accessible epitopes on immune cells in the tumor microenvironment

T. V. Sekar, E. Elghonaimy, K. L. Swancutt, S. Diegeler, I. Gonzalez, C. Hamilton, P. Q. Leung, J. Meiler, C. E. Martina, M. Whitney, T. A. Aguilera

This study introduces INSPIRE-seq, a method to identify nanobodies targeting immune cells in the tumor microenvironment, revealing a dendritic cell-binding nanobody that interacts with PHB2.

bioRxiv · May 26, 2021Bioengineering